Hypertensive retinopathy is a systemic warning. Vein occlusion is treated through its macular oedema and neovascularisation. Arterial occlusion is an emergency for the eye and for the brain.
Terminology and draft status
Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.
01Read hypertensive retinopathy as a systemic warning
The eye is a target organ of systemic hypertension: changes may appear in the retina, the choroid and, in some cases, the optic disc. Most patients have no visual symptoms; some notice blurred or reduced vision. Measure blood pressure, examine the dilated fundus and interpret the fundus together with the systemic findings. An ophthalmologist may detect previously unknown hypertension, but this depends on the care pathway and never replaces internal-medicine assessment. 1 2 5
Chronic hypertensive changes include generalised or focal narrowing of the retinal arterioles, usually bilateral, and arteriovenous crossing signs (nicking, Gunn sign), where the artery compresses the vein. Arteriosclerosis may appear as copper wiring or, in severe cases, silver wiring. Cotton-wool spots are fluffy white lesions caused by infarcts of the retinal nerve fibre layer and appear hypofluorescent on fluorescein angiography; flame-shaped haemorrhages follow the nerve fibre layer. These are optical descriptions, not direct histological proof of vessel-wall disease. 1 2
In acute or malignant hypertension the original teaching describes a systolic pressure above 200 mmHg. Current emergency definitions are wider: a pressure of at least 180/110 mmHg together with acute organ injury. Retinal flame haemorrhages, cotton-wool spots and disc oedema are signs of that injury; they are not restricted to a systolic value above 200 mmHg and not confined to grade 4. Additional findings include hard exudates, sometimes arranged as a macular star, retinal oedema and optic disc swelling. Signs of chronic hypertension may coexist. 1 2 5
Keith-Wagener-Barker grading runs from grade 0 (no visible change) to grade 1 (mild narrowing), grade 2 (clearer narrowing with arteriovenous crossing signs), grade 3 (haemorrhages, exudates or cotton-wool spots) and grade 4 (disc oedema). The grade describes the fundus; it is not a substitute for blood-pressure measurement and systemic assessment. Grade 4 is an emergency, and severe hypertension with acute organ injury must not wait for it. 1 2
02Investigate and refer without delaying acute care
Ask whether hypertension is already known and whether diabetes, kidney disease or other vascular risk factors are present. Examine both eyes with a dilated pupil, measure blood pressure in the practice and document the disc, macula and vessel changes. Chronic signs usually need referral to internal medicine or cardiology for investigation and treatment; acute signs, especially grade 4, need same-day emergency assessment. 1 2
The primary treatment is control of systemic hypertension, agreed with the treating physician; no specific antihypertensive drug regimen is given here. The original proposes ophthalmological review every 2–3 months initially and every 6–12 months later. That is an individual follow-up proposal, not an emergency schedule, and it changes with the clinical course. 1 2
Three practical questions remain useful. Acute hypertensive injury may occur with haemorrhages and cotton-wool spots, with or without disc oedema; grades alone do not reliably date the disease. Isolated disc oedema without other hypertensive signs should raise other causes, including raised intracranial pressure from a tumour; always check blood pressure, because papilloedema in malignant hypertension is usually accompanied by arteriovenous nicking, narrowing, haemorrhages and oedema. Paediatric hypertensive retinopathy is rare, but it can be the first presentation and is not limited to children already known to be severely ill; look for renal disease or phaeochromocytoma, measure blood pressure with an appropriate cuff and involve paediatric services. 1 2
03Weigh the risk factors without treating a number as a diagnosis
Retinal vein occlusion is the second most common retinal vascular disease after diabetic retinopathy. The original lists age above 60 years, hypertension in more than 66% of patients and hyperlipidaemia in about 33%. These figures come from unverified populations; they describe associations in a group and are not an individual risk or a diagnostic test. 1 2
Ocular risk factors include a previous vein occlusion in the fellow eye, primary open-angle glaucoma, external pressure on the vein (for example orbital phlegmon or tumour) and hyperopia. Systemic risk factors are diabetes mellitus, smoking, blood disorders (chronic leukaemia, macroglobulinaemia, sickle-cell disease, thrombophilia), oral contraceptives, dehydration, vasculitis such as Behçet disease or sarcoidosis, and chronic renal failure. Oestrogen exposure needs individual assessment rather than a blanket rule. These are anatomical, mechanical or systemic contributors; most are associations and their presence does not prove causation in one eye. 1 2
Look for atherosclerotic risk rather than ordering every thrombophilia test. A routine antiphospholipid or thrombophilia panel for every isolated vein occlusion, or for every young patient, is not supported; select tests for atypical, bilateral or recurrent disease, young age with a suggestive history, or other systemic indications. There is no established anticoagulant or antiplatelet treatment for ocular vein occlusion alone; such treatment follows the systemic indication and the treating physician's decision. 2 3
04Localise the occlusion before naming the disease
In central retinal vein occlusion the obstruction is described at the lamina cribrosa or behind it. The central artery and vein share an adventitial sheath, so atherosclerosis of the artery can compress the vein, producing turbulent flow, endothelial injury and thrombosis. This artery-compression model is a teaching model, not the only mechanism, and the exact obstruction site is not always precisely behind the lamina. 1 2
Branch retinal vein occlusion occurs anterior to the lamina cribrosa, typically at an arteriovenous crossing where the artery compresses the vein. The superotemporal quadrant is the most common site, and branch occlusion is roughly three times more common than central occlusion. 1 2
Hemiretinal vein occlusion affects either the upper or the lower half of the retina. It is a distinct entity, not a large branch occlusion: management follows central or branch occlusion principles according to the degree of ischaemia and macular oedema, and the affected half should be described explicitly. 1 2
05Recognise central vein occlusion and its late consequences
After venous obstruction, blood stagnates and the retina becomes hypoxic. Hypoxia damages capillary endothelial cells, so fluid and blood leak: haemorrhages, retinal oedema and protein-rich exudates appear. Hypoxic nerve-fibre infarction produces cotton-wool spots. These steps explain the findings but do not predict an individual course. 1 2
Central vein occlusion usually causes sudden, painless, unilateral visual loss. The severity varies with the ischaemic status: some eyes retain useful acuity, others see only counting fingers or worse. Ask about duration, the fellow eye, vascular risk factors and medication, and examine both eyes. 1 2
The classic blood-and-thunder or stormy-sunset appearance shows diffuse haemorrhages in all four quadrants, dilated and tortuous veins, and disc oedema with hyperaemia. Cotton-wool spots may be present. Macular oedema is the most common cause of visual deterioration and is the finding that most often requires treatment. 1 2
Late findings include optociliary collateral vessels (shunt vessels) at the disc, which develop in response to ischaemia and are usually a favourable prognostic sign. They do not prove that glaucoma or neovascularisation is absent. Neovascularisation may arise at the disc (NVD), in the retina (NVE), on the iris (NVI, rubeosis iridis) or in the anterior-chamber angle (NVA); each site needs examination and, where possible, gonioscopy. 1 2 3
The division into non-ischaemic and ischaemic central occlusion is descriptive. The table compares frequency, visual acuity, pupillary reaction, ophthalmoscopic appearance, fluorescein angiography, complications and prognosis. The features overlap, the category can change over time, and no single criterion should be used alone to label an eye. 1 2
| Feature | Non-ischaemic CRVO (mild/perfusion type) | Ischaemic CRVO (severe) |
|---|---|---|
| Frequency | More common | Less common |
| Visual acuity | Typically better than 6/60 (0.1) | Typically worse than 6/60, often counting fingers or worse |
| Pupillary reaction | No or only a mild relative afferent pupillary defect (RAPD) | Obvious RAPD present |
| Ophthalmoscopy | Mild to moderate haemorrhages, mild macular oedema, mild disc swelling | Marked haemorrhages, numerous cotton-wool spots, severe oedema |
| Fluorescein angiography | Good capillary perfusion, delayed arteriovenous transit, masking by haemorrhage, late leakage | Extensive non-perfused areas (>10 disc areas), masking and strong leakage. The >10 disc-area figure came from seven-field imaging and is not a universal wide-field threshold. |
| Complications | Lower risk of neovascularisation | High risk (50%) of neovascularisation of the iris or angle within 2–4 months, which can lead to 100-day glaucoma (neovascular glaucoma). The 50% figure and the 2–4-month window are original teaching values with unverified definitions and are not individual risks. |
| Prognosis | Good if no conversion to the ischaemic form occurs (about 15% convert). Acuity may return to normal in 50% of patients. Both percentages are original, with undefined follow-up. | Poor. The main causes of visual loss are chronic macular oedema and secondary atrophy. |
06Classify with imaging and examine the whole patient
Non-ischaemic occlusion is more common, usually has acuity better than 6/60 (0.1) and shows no or only a mild relative afferent pupillary defect, with mild to moderate haemorrhages, mild macular oedema and mild disc swelling. Ischaemic occlusion is less common, typically has acuity worse than 6/60, often counting fingers or worse, an obvious relative afferent pupillary defect and marked haemorrhages, numerous cotton-wool spots and severe oedema. 1 2
Fluorescein angiography in non-ischaemic occlusion shows good capillary perfusion, delayed arteriovenous transit, masking by haemorrhage and late leakage. Ischaemic occlusion shows extensive non-perfused areas, conventionally more than 10 disc areas, with masking and strong leakage. That 10-disc-area figure came from seven-field imaging; it is not a universal wide-field threshold, and macular ischaemia is not the same as global central occlusion ischaemia. 1 2
The original teaching gives a 50% risk of neovascularisation of the iris or angle within 2–4 months, leading to 100-day glaucoma (neovascular glaucoma). These values have unverified definitions and time frames and are not individual risks. The 2022 RCOphth guideline describes about 30% conversion over 3 years, which differs from the original 15% with undefined follow-up. Anti-VEGF treatment does not eliminate the risk of neovascularisation, and stopping it requires continued monitoring. 1 2 3
Prognosis in non-ischaemic occlusion is good if no conversion occurs; the original states that about 15% convert and that acuity may return to normal in 50% of patients. Both figures are original teaching values with undefined definitions. In ischaemic occlusion the prognosis is poor, with chronic macular oedema and secondary atrophy as the main causes of visual loss. Reassess the category when the examination or imaging changes. 1 2
Examination starts with visual acuity, pupil assessment and a relative afferent pupillary defect, then slit lamp, gonioscopy and a dilated fundus examination of both eyes. Optical coherence tomography (OCT) is central to assessing and following macular oedema; fluorescein angiography grades ischaemia, identifies non-perfused areas and detects neovascularisation. The original describes fluorescein angiography as an insurance requirement in Germany; its current national validity is unverified and local requirements must be checked. Electroretinography can show a reduced b-wave in ischaemic forms, but it is supportive and not a routine requirement. Systemically, measure blood pressure and request fasting glucose, HbA 1c, full blood count, inflammatory markers (ESR, CRP) and a lipid profile. In young patients look specifically for coagulation disorders and blood dyscrasias instead of running a routine panel, and refer to internal medicine or cardiology for cardiovascular risk assessment. 1 2
The main differential diagnoses are usually separated by distribution and course. Diabetic retinopathy has its own stages and features. Grade 4 hypertensive retinopathy can look very similar, but it is typically bilateral, shows fewer diffuse haemorrhages and no delayed venous filling on fluorescein angiography; neovascularisation is atypical. Hyperviscosity syndromes such as multiple myeloma or polycythaemia are usually bilateral. In ocular ischaemic syndrome the haemorrhages are typically deeper and venous tortuosity is absent. These features are clues, not single decisive signs; when doubt remains, vascular imaging and the systemic work-up decide. 1 2
07Treat macular oedema and judge the evidence honestly
Treatment does not reopen the vein; it treats the complications. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is first-line for macular oedema. The original threshold of acuity worse than 6/9 or central retinal thickness above 250 µm is a teaching example, not a universal cutoff: treat when oedema threatens or reduces vision, and document the baseline. 2 3
Ranibizumab was studied in BRAVO and CRUISE, aflibercept in VIBRANT, COPERNICUS and GALILEO. In BALATON and COMINO, monthly faricimab was compared with aflibercept for 24 weeks in 553 eyes with branch occlusion and 729 eyes with central or hemiretinal occlusion. Visual gains were 16.9 versus 17.5 letters and 16.9 versus 17.3 letters, meeting non-inferiority with 95.03% intervals. The anatomical leakage result was nominal; this is not proof of superior vision or of efficacy at longer intervals. 1 3 9
Bevacizumab is used off-label for retinal vein occlusion. In SCORE 2, 362 eyes with central or hemiretinal occlusion received monthly bevacizumab (182 eyes) or aflibercept (180 eyes) for 6 months; 348 completed, with gains of 18.6 and 18.9 letters and a difference of −0.14 letters (one-sided 97.5% confidence interval −3.07 to infinity) within a 5-letter margin. This supports non-inferiority on that outcome, not equal rare-event safety or proof in branch occlusion. 7
In LEAVO, 463 eyes with central occlusion were followed for 100 weeks: gains were 12.5 letters with ranibizumab, 15.1 with aflibercept and 9.8 with bevacizumab. Aflibercept versus ranibizumab gave an adjusted difference of 2.23 letters (95% confidence interval −2.17 to 6.63), meeting non-inferiority, while bevacizumab versus ranibizumab gave −1.73 letters (95% confidence interval −6.12 to 2.67), which is inconclusive rather than proof of inferiority or equivalence. The original C-CATT citation could not be verified as a vein-occlusion trial and may be a misnomer; it is retained as an unresolved citation, not as evidence of equal efficacy. 8
Schedules follow the licensed product and the protocol. The original mentions review every 4–8 weeks under a pro re nata (as-needed) strategy; that interval depends on the protocol, and initial monthly dosing until maximum stable acuity is a common starting principle, not an automatic fixed number of injections for every eye. Record acuity, OCT and pressure, and review the interval at each visit. 2 3
Intravitreal corticosteroids are an alternative for selected eyes, particularly when anti-VEGF alone is insufficient or impractical. The GENEVA study of the dexamethasone implant described visual improvement, especially between day 30 and day 90. The original calls this second-line and describes triamcinolone as superior to macular laser in the SCORE study; in fact SCORE-CRVO compared triamcinolone with observation, and the branch-occlusion arm used a different design with grid laser, so superiority of triamcinolone over laser cannot be generalised to all vein occlusions. Steroids raise intraocular pressure and cataract risk and are contraindicated in advanced glaucoma, suspected infection or according to implant-specific criteria such as lens-capsule integrity; check the label and the individual eye. 1 3
Macular grid laser was the historical standard and is now largely replaced by intravitreal treatment. It may be considered for chronic macular oedema, for example when intravitreal treatment is unavailable. The original describes light burns of 50–100 µm placed on angiographic leakage areas while sparing the foveal avascular zone; these are historical examples, not universal laser settings. 1 2
08Treat new vessels, plan follow-up and manage branch occlusion
Once neovascularisation is detected at the iris, angle or retina, panretinal photocoagulation is the standard treatment. The original mentions 1500–2000 laser spots; this is a historical example, not a universal prescription. For branch occlusion, sectoral panretinal photocoagulation treats the affected sector rather than the whole retina. Anti-VEGF can be given as an adjunct to obtain faster regression, but it does not replace photocoagulation or the need for continued monitoring. 1 3 10
Prophylactic photocoagulation before neovascularisation is not established. In the Central Vein Occlusion Study, 90 eyes were randomised to immediate treatment and 91 to observation; the endpoint was at least 2 clock hours of iris neovascularisation or any angle neovascularisation, and the baseline-adjusted comparison showed no significant benefit. Among eyes that developed neovascularisation, regression by 1 month was reported in 18 of 32 versus 4 of 18 in the described subsets; these are not baseline randomised comparisons. Prophylaxis may be considered individually when reliable follow-up is impossible. 1 10
Follow-up depends on the type, the treatment and the risk of neovascularisation. The original proposes monthly review for the first 6 months in ischaemic central occlusion, then every 2–3 months for up to 2 years, and a review after 3 months in non-ischaemic occlusion. These are examples: an actively treated eye is seen according to its treatment schedule, and monitoring must continue after anti-VEGF is stopped because new vessels can appear. 1 2
Branch occlusion is often asymptomatic when the periphery is affected; otherwise it causes a field defect or mildly reduced acuity depending on location. Signs are sectoral superficial haemorrhages, cotton-wool spots and oedema, with dilated tortuous veins distal to the occlusion. Neovascularisation of the retina or disc can occur, and prognosis depends on macular involvement. Acute findings often resolve within 6–12 months, leaving venous sheathing and sclerosis, but resolution is not guaranteed; collateral vessels develop over weeks to months and are a good prognostic sign. 1 2
Systemic assessment is the same as for central occlusion. If acuity is good, above 6/9, selected observation with follow-up is reasonable, but important macular oedema should not be observed instead of treated. For significant oedema with acuity below 6/9, intravitreal anti-VEGF or steroids are the treatment of choice; if intravitreal treatment is unavailable, grid laser may be considered after 3 months of observation. Sectoral photocoagulation is indicated for neovascularisation; the original claim that it reduces vitreous haemorrhage from 60% to 30% could not be verified against the primary report's denominator and timing and is retained only as an unverified teaching statement. Pars plana vitrectomy is indicated for non-clearing vitreous haemorrhage or tractional retinal detachment. For hemiretinal occlusion, follow central or branch principles according to ischaemia and oedema and do not treat the unaffected half. 1 2 3
09Treat arterial occlusion as an emergency for eye and brain
The inner retina is supplied by the central retinal artery; the outer retina is supplied by the ciliary arteries through the choriocapillaris. The ophthalmic artery is the first branch of the internal carotid artery and gives rise to the central retinal and ciliary arteries. In central retinal artery occlusion an embolus usually lodges at the arterial orifice on the lamina cribrosa, most often from an atheromatous carotid plaque. Cholesterol emboli (Hollenhorst plaques) are yellow and glistening and come from the carotid; platelet-fibrin emboli are whitish in thrombotic disease; calcium emboli are chalky-white and come from heart valves. The appearance suggests a source but cannot prove it. 1 4
Central retinal artery occlusion causes sudden, severe, painless, unilateral visual loss. Acutely, the inner retinal layers look cloudy, oedematous and white. The cherry-red spot appears because the thin foveola transmits the colour of the perfused choroid while the surrounding retina is ischaemic and swollen; it may be absent initially. Other signs are a relative afferent pupillary defect, narrowed arteries and boxcar segmentation of stagnant blood flow. Later the oedema resolves, the retina looks transparent again, and arterial narrowing with a pale disc from optic atrophy remains. 1 4
Central retinal artery occlusion is a stroke of the eye. The risk of cerebral or myocardial infarction is strongly increased in the following 7–10 days, but that is not the only risk window. Refer immediately to a stroke unit or emergency department for carotid duplex ultrasound, CT angiography and echocardiography. Ancillary OCT or fluorescein angiography must not delay referral. Angiography shows markedly delayed or absent arterial filling, blocked background fluorescence from oedema and preserved choroidal filling; choroidal filling may not be normal in ophthalmic artery occlusion or giant cell arteritis. 3 4
Giant cell arteritis is an important differential diagnosis in older patients. The original gives 1–2% of arterial-occlusion patients and an age above 55 years; both come from unverified populations. Consider the diagnosis from about age 50 and do not exclude it at 51. Ask about headache, jaw claudication and scalp tenderness; ESR, CRP and platelets are often raised, but normal markers do not exclude the disease. If suspicion is high, give high-dose systemic corticosteroids immediately to protect the fellow eye and do not wait for biopsy or imaging; temporal artery biopsy can confirm the diagnosis. 1 3 4
The original lists ocular measures to try within the first 24–48 hours: supine posture, ocular massage with 10 seconds of pressure and 5 seconds of release for 3–5 minutes, anterior-chamber paracentesis, pressure-lowering drugs such as timolol, apraclonidine and acetazolamide, and vasodilatation with a paper bag or carbogen (95% oxygen, 5% carbon dioxide). These are unproven historical measures, not a recommended routine or a safe waiting window. The current guideline finds no significant benefit and some harm and risk; a paper bag is unsafe because of hypoxia and must not be used at home as self-treatment. The original 90–120 minutes is not a universal human irreversibility threshold and is never a reason to stop urgent referral. 1 4
Thrombolysis is not a blanket treatment for every arterial occlusion. The original cites the EAGLE study as showing no clear benefit with a high risk of intracranial haemorrhage. In THEIA, 70 patients within 4.5 hours were randomised to alteplase or aspirin; improvement of at least 0.3 logMAR at 1 month occurred in 19 of 29 versus 13 of 27, an unadjusted risk difference of 17.4 percentage points (95% confidence interval −11.8 to 46.5). The trial was underpowered with missing data and one asymptomatic intracranial haemorrhage. In TenCRAOS, 78 patients within 4.5 hours received tenecteplase (40) or aspirin (38); 30-day acuity of 20/100 or better occurred in 8 of 40 versus 9 of 38, a risk difference of −3.7 percentage points (95% confidence interval −22 to 14.7), p=0.69, with one fatal intracranial haemorrhage. Neither trial demonstrates superiority, and the doses are not a prescription. 4 11 12
10Finish with branch occlusion, cilioretinal sparing and the guideline frame
Branch arterial occlusion causes sudden sectoral field loss, with a sector of superficial white retinal opacity; the embolus is sometimes visible in the affected arteriole. Systemic assessment is the same as for central occlusion, neovascularisation is rare, and follow-up is still required. The cilioretinal artery is present in 18–30% of eyes, arises from the ciliary arteries and supplies part of the macula; its occlusion causes a central scotoma. With a simultaneous central occlusion, an intact cilioretinal artery can preserve central acuity because the fovea remains perfused, but it does not supply every fovea and does not guarantee the outcome. 1 3 4
The original names S1, S2, S3 and S4 guideline levels. The AWMF classification defines S1, S2e, S2k and S3, and there is no S4 category. The original also does not define the German professional association (BVA) or the German Ophthalmological Society (DOG) structures, so no formal grade should be assigned. A German 2018 vein-occlusion statement exists but was not read for this copy and its current revision is unverified. The same applies to the original statement that fluorescein angiography and bevacizumab are mandatory for insurance coverage in Germany: distinguish medical indication from local reimbursement, and never delay urgent care for either. 1 6
The overview table condenses every topic of the lecture for revision: hypertensive retinopathy, central and branch vein occlusion, macular-oedema and neovascularisation treatment, central artery occlusion with giant cell arteritis and acute therapy, and the cilioretinal artery. The guideline-level column records only what the original source stated, which is that no formal level was given. Use the table to check that a topic has been covered, not as a treatment protocol. 1 2 3
| Topic | Key concepts | Evidence / clinical signs | Guideline level (if given) | Notes / exceptions |
|---|---|---|---|---|
| Hypertensive retinopathy | Classification grades 1–4 | Grade 1: arterial narrowing; grade 2: arteriovenous crossing signs; grade 3: haemorrhages or exudates; grade 4: disc oedema | Not given in the original source | Grade 4 is an emergency. The diagnosis can be sight- and life-saving. A pressure of at least 180/110 mmHg with acute organ injury is the wider emergency context; systolic >200 mmHg is not the only cutoff. |
| Central retinal vein occlusion | Ischaemic versus non-ischaemic | Non-ischaemic: acuity >6/60, no RAPD. Ischaemic: acuity <6/60, RAPD, >10 disc areas of non-perfusion on fluorescein angiography. | Not given in the original source | Ischaemic occlusion carries a 50% risk of neovascularisation and neovascular glaucoma in the original teaching; the values and time frame are unverified. |
| Central retinal vein occlusion (continued; original cell blank) | Treatment of macular oedema | Anti-VEGF (ranibizumab, aflibercept, off-label bevacizumab), steroids (dexamethasone implant), laser | Not given in the original source | Bevacizumab is often first-line in Germany; this is a local practice and reimbursement statement, not a verified national rule. Steroids can cause cataract and a pressure rise. |
| Central retinal vein occlusion (continued; original cell blank) | Treatment of neovascularisation | Panretinal photocoagulation (PRP) | Not given in the original source | Indicated once neovascularisation is present (iris, angle, retina). Anti-VEGF is an adjunct and does not remove the need for monitoring. |
| Branch retinal vein occlusion | Occlusion at an arteriovenous crossing | Sectoral haemorrhages, oedema. Most common quadrant: superotemporal. | Not given in the original source | Macular-oedema treatment as in central occlusion. Sectoral PRP for neovascularisation; not full PRP. |
| Central retinal artery occlusion | Ophthalmic emergency | Cherry-red spot, sudden severe visual loss, RAPD | Not given in the original source | Immediate referral to a stroke unit or emergency department. High risk of systemic infarction. |
| Central retinal artery occlusion (continued; original cell blank) | Important differential diagnosis: giant cell arteritis | Patients >55 years, raised ESR/CRP. Consider from age 50; normal markers do not exclude the disease. | Not given in the original source | If suspected, immediate systemic steroids to protect the fellow eye; do not wait for biopsy or imaging. |
| Central retinal artery occlusion (continued; original cell blank) | Acute therapy | Ocular massage, pressure lowering, paracentesis | Not given in the original source | Evidence is very limited and these are unproven historical measures. Irreversible damage was said to occur after 90–120 minutes; this is not a universal human threshold and never a reason to delay referral. |
| Cilioretinal artery | Preserves central visual acuity | Supplies the macula; in central artery occlusion an intact cilioretinal artery can preserve visual acuity | Not given in the original source | Anatomical variant in 18–30% of eyes. It does not supply every fovea and does not guarantee preserved acuity. |
What are the main learning points of the lecture Briefing document: retinal vascular disease?
Hypertensive retinopathy is a systemic warning that ranges from arterial narrowing to disc oedema. Retinal vein occlusion is treated through macular oedema and neovascularisation, with anti-VEGF, steroids, laser and monitoring. Retinal artery occlusion is an emergency for the eye and the brain: refer immediately, consider giant cell arteritis, and do not present unproven acute measures as routine treatment.
Which findings require urgent assessment?
Rapid visual deterioration, severe pain, marked inflammation, a rise in intraocular pressure, suspected infection or a neurological cause. Sudden painless visual loss suggests arterial occlusion and needs immediate stroke or emergency assessment; grade 4 hypertensive retinopathy, new neovascularisation and suspected giant cell arteritis also need same-day care.
References and access status
- 1Immutable original export; retinal vascular disease lecture
Complete export read; original attribution, recording, transcript, slides and cases not independently verified.
- 2RCOphth 2022 retinal vein occlusion guideline: executive summary
Cached PDF; selected actual printed pages 2–5 read 13 November 2026. It is 2022 evidence, not a new 2026 guideline because of the download folder date. Full guideline, algorithms and cited reports unread.
- 3AAO Preferred Practice Pattern: retinal vein occlusions, 2024 with June 2026 update
Official indexed update and highlights read 13 November 2026; not a fresh complete PPP or full evidence appraisal.
- 4AAO Preferred Practice Pattern: retinal and ophthalmic artery occlusions, 2024
Actual cached PDF; selected printed pages 286–289 on rationale, referral, imaging and acute management reread 13 November 2026. Complete PPP and cited primary reports unread.
- 5ESC 2024 guidelines: hypertension
Selected indexed primary paragraph on hypertensive emergency read 13 November 2026; not the full guideline and no antihypertensive regimen adopted.
- 6AWMF: classification of guideline types
Selected indexed classification page read 13 November 2026: S1, S2e, S2k and S3; no S4 category.
- 7SCORE 2 randomised trial: bevacizumab versus aflibercept in central or hemiretinal vein occlusion
Complete actual NCBI abstract read 13 November 2026; full report, protocol and supplement unread.
- 8LEAVO randomised trial: ranibizumab, aflibercept and bevacizumab in central vein occlusion
Complete actual NCBI abstract read 13 November 2026; full report, protocol and supplement unread.
- 9BALATON and COMINO phase 3 trials: faricimab versus aflibercept in retinal vein occlusion
Complete actual NCBI abstract read 13 November 2026; full reports and later-phase data unread.
- 10Central Vein Occlusion Study: randomised trial of immediate versus observation for prophylactic panretinal photocoagulation
Complete actual NCBI abstract read 13 November 2026; full report and subsets unread.
- 11THEIA phase 3 trial: alteplase versus aspirin in central retinal artery occlusion
Complete actual NCBI abstract read 13 November 2026; full report, protocol and safety adjudication unread.
- 12TenCRAOS phase 3 trial: tenecteplase versus aspirin in central retinal artery occlusion
Complete actual NCBI abstract read 13 November 2026; full report, protocol and bleeding adjudication unread.
Original lecture link
- Original exported lecture link
Export link only; recording, transcript, slides and cases not independently verified.
For patients
This lecture compares three retinal vascular problems: damage from high blood pressure, blocked retinal veins and blocked retinal arteries. They can look similar, but they need different examinations and different urgency.
The content is for orientation and does not replace an individual examination by an ophthalmologist. Your symptoms, blood pressure and eye findings decide which tests and treatment you need.
Seek medical help immediately for sudden visual loss, severe pain or a new visual-field defect. A suspected blocked retinal artery is an emergency for the eye and the brain and must not wait.
Sudden painless visual loss needs immediate assessment. Suspected retinal artery occlusion is a stroke-equivalent emergency; grade 4 hypertensive retinopathy, new neovascularisation and suspected giant cell arteritis also need same-day specialist care.